Sökning: onr:"swepub:oai:DiVA.org:uu-475451" > European Society of...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04782naa a2200589 4500 | |
001 | oai:DiVA.org:uu-475451 | |
003 | SwePub | |
008 | 220602s2022 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4754512 URI |
024 | 7 | a https://doi.org/10.1016/j.cmi.2021.11.0252 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Paul, Mical4 aut |
245 | 1 0 | a European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine) |
264 | 1 | b Elsevier,c 2022 |
338 | a print2 rdacarrier | |
520 | a ScopeThese ESCMID guidelines address the targeted antibiotic treatment of third-generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy.MethodsAn expert panel was convened by ESCMID. A systematic review was performed including randomized controlled trials and observational studies, examining different antibiotic treatment regimens for the targeted treatment of infections caused by the 3GCephRE, carbapenem-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii. Treatments were classified as head-to-head comparisons between individual antibiotics and between monotherapy and combination therapy regimens, including defined monotherapy and combination regimens only. The primary outcome was all-cause mortality, preferably at 30 days and secondary outcomes included clinical failure, microbiological failure, development of resistance, relapse/recurrence, adverse events and length of hospital stay. The last search of all databases was conducted in December 2019, followed by a focused search for relevant studies up until ECCMID 2021. Data were summarized narratively. The certainty of the evidence for each comparison between antibiotics and between monotherapy and combination therapy regimens was classified by the GRADE recommendations. The strength of the recommendations for or against treatments was classified as strong or conditional (weak).RecommendationsThe guideline panel reviewed the evidence per pathogen, preferably per site of infection, critically appraising the existing studies. Many of the comparisons were addressed in small observational studies at high risk of bias only. Notably, there was very little evidence on the effects of the new, recently approved, β-lactam/β-lactamase inhibitors on infections caused by carbapenem-resistant Gram-negative bacteria. Most recommendations are based on very-low- and low-certainty evidence. A high value was placed on antibiotic stewardship considerations in all recommendations, searching for carbapenem-sparing options for 3GCephRE and limiting the recommendations of the new antibiotics for severe infections, as defined by the sepsis-3 criteria. Research needs are addressed. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
653 | a Acinetobacter baumannii | |
653 | a Carbapenem-resistant bacteria | |
653 | a ESCMID | |
653 | a GRADE | |
653 | a Multidrug resistant bacteria | |
700 | 1 | a Carrara, Elena4 aut |
700 | 1 | a Retamar, Pilar4 aut |
700 | 1 | a Tängdén, Thomasu Uppsala universitet,Infektionsmedicin4 aut0 (Swepub:uu)thota437 |
700 | 1 | a Bitterman, Roni4 aut |
700 | 1 | a Bonomo, Robert A.4 aut |
700 | 1 | a de Waele, Jan4 aut |
700 | 1 | a Daikos, George L.4 aut |
700 | 1 | a Akova, Murat4 aut |
700 | 1 | a Harbarth, Stephan4 aut |
700 | 1 | a Pulcini, Celine4 aut |
700 | 1 | a Garnacho-Montero, José4 aut |
700 | 1 | a Seme, Katja4 aut |
700 | 1 | a Tumbarello, Mario4 aut |
700 | 1 | a Lindemann, Paul Christoffer4 aut |
700 | 1 | a Gandra, Sumanth4 aut |
700 | 1 | a Yu, Yunsong4 aut |
700 | 1 | a Bassetti, Matteo4 aut |
700 | 1 | a Mouton, Johan W.4 aut |
700 | 1 | a Tacconelli, Evelina4 aut |
700 | 1 | a Rodríguez-Baño, Jesús4 aut |
710 | 2 | a Uppsala universitetb Infektionsmedicin4 org |
773 | 0 | t Clinical Microbiology and Infectiond : Elsevierg 28:4, s. 521-547q 28:4<521-547x 1198-743Xx 1469-0691 |
856 | 4 | u http://www.clinicalmicrobiologyandinfection.com/article/S1198743X21006790/pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-475451 |
856 | 4 8 | u https://doi.org/10.1016/j.cmi.2021.11.025 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.